If retinoids are to be used as therapeutic agents for AD, it is important to identify the specific RAR(s) involved in this process in order to discover relevant drug targets, thus overcoming deficiencies in atRA, which can activate all of the RARs, with potential toxic effects. Here, RARA is linked to Alzheimer disease.